Abbvie's strategy has focused on delivering strong financial results, advancing and investing in its pipeline and returning value to shareholders while ensuring a strong, sustainable growth business over the long term. The company intends to continue to advance its mission by growing revenues through diversifying revenue streams, ensuring strong commercial execution of new product launches, and driving late-stage pipeline assets to the market. Abbvie anticipates several regulatory submissions and key data readouts from clinical trials in the next 12 months, which reflects its commitment to operational flexibility and adaptability in response to market demands. The combination of Abbvie and Allergan is expected to create a diverse entity with leadership positions across various therapeutic areas, enhancing Abbvie's existing product portfolio and pipeline. The company remains committed to driving continued expansion of operating margins through productivity initiatives in supply chain and ongoing efficiency programs, which are essential for maintaining performance under pressure. Abbvie's financial performance in 2019 included delivering worldwide net revenues of $33.3 billion, reflecting the company's ability to absorb strain and preserve functioning despite external pressures such as international competition and market dynamics. The company has invested in its pipeline, which includes approximately 60 compounds in clinical development, demonstrating its focus on innovation and resilience strategies to confront and benefit from sudden disruptive changes. Abbvie's operational management includes effective management of biosimilar erosion and the favorable impact of pipeline products, which are critical for maintaining competitive advantage. The company’s commitment to research and innovation is evident in its long-term success, which depends on its ability to discover and develop innovative pharmaceutical products. Abbvie's financial flexibility is supported by cash flows from operations and access to capital, which are vital for sustaining growth objectives and responding to unforeseen challenges. The company monitors economic conditions and customer creditworthiness to mitigate credit risk, reflecting a proactive approach to risk management. Abbvie's operational continuity is further supported by its strategic planning and resource management, which are designed to optimize manufacturing and administrative costs. The company's ability to generate cash flows from operations and issue debt may be adversely affected by material declines in demand or other unfavorable changes in business conditions, highlighting the importance of organizational resilience in navigating complex situations. Abbvie's focus on stakeholder engagement and collaboration networks is integral to its resilience strategies, enabling the organization to adapt and thrive in turbulent markets. The company’s strategic response to environmental disruptions includes leveraging its existing capabilities and fostering a culture of learning and innovation, which are essential for ensuring organizational health and effectiveness.